LOLLI, CRISTIAN
 Distribuzione geografica
Continente #
AS - Asia 2.857
NA - Nord America 2.726
EU - Europa 1.708
AF - Africa 187
SA - Sud America 152
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.633
Nazione #
US - Stati Uniti d'America 2.686
SG - Singapore 869
VN - Vietnam 814
CN - Cina 581
IT - Italia 438
HK - Hong Kong 272
GB - Regno Unito 258
DE - Germania 199
SE - Svezia 184
FR - Francia 127
BR - Brasile 106
IN - India 89
NL - Olanda 71
CH - Svizzera 70
IE - Irlanda 69
RU - Federazione Russa 63
FI - Finlandia 56
TG - Togo 48
KR - Corea 41
ZA - Sudafrica 37
CI - Costa d'Avorio 32
UA - Ucraina 31
BD - Bangladesh 28
JP - Giappone 28
SC - Seychelles 27
TH - Thailandia 25
AT - Austria 24
BG - Bulgaria 23
CA - Canada 22
BE - Belgio 21
EE - Estonia 21
PH - Filippine 21
AR - Argentina 16
PL - Polonia 16
ID - Indonesia 14
TW - Taiwan 14
JO - Giordania 10
NG - Nigeria 10
CL - Cile 9
ES - Italia 9
GR - Grecia 9
IQ - Iraq 9
CO - Colombia 8
MX - Messico 8
GH - Ghana 7
IR - Iran 7
TR - Turchia 7
EC - Ecuador 5
EG - Egitto 5
MY - Malesia 5
PK - Pakistan 5
KE - Kenya 4
LT - Lituania 4
NI - Nicaragua 4
VE - Venezuela 4
AL - Albania 3
MA - Marocco 3
PE - Perù 3
SN - Senegal 3
TN - Tunisia 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
AZ - Azerbaigian 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
KZ - Kazakistan 2
MD - Moldavia 2
MU - Mauritius 2
RO - Romania 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
DZ - Algeria 1
GT - Guatemala 1
IL - Israele 1
JM - Giamaica 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
LY - Libia 1
MG - Madagascar 1
NO - Norvegia 1
NP - Nepal 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TZ - Tanzania 1
UY - Uruguay 1
Totale 7.633
Città #
Singapore 645
Ashburn 347
Chandler 277
San Jose 267
Hong Kong 243
Southend 223
Hanoi 203
Ho Chi Minh City 200
Fairfield 174
Santa Clara 113
Wilmington 97
Hefei 94
Houston 82
Beijing 74
Bologna 73
Princeton 72
Los Angeles 71
Dublin 68
New York 66
Bern 65
Woodbridge 65
Seattle 64
Dong Ket 60
Cambridge 58
Ann Arbor 57
Boardman 51
Lauterbourg 49
Lomé 48
Helsinki 46
Council Bluffs 43
Seoul 39
Rome 38
Da Nang 33
Abidjan 32
Turin 32
Frankfurt am Main 31
Nanjing 28
Haiphong 27
Buffalo 25
Milan 25
Sofia 23
Berlin 22
Padova 22
Westminster 22
Dallas 21
Jinan 20
Brussels 19
Redmond 19
Munich 18
Redondo Beach 18
Tokyo 18
Guangzhou 16
San Diego 16
Bangkok 14
Shanghai 14
Johannesburg 13
Vienna 13
Zhengzhou 13
Düsseldorf 11
Amman 10
Falls Church 10
Jiaxing 10
Orem 10
Ravenna 10
São Paulo 10
Warsaw 10
Changsha 9
Des Moines 9
Fort Worth 9
Jakarta 9
London 9
Phoenix 9
Abeokuta 8
Can Tho 8
Falkenstein 8
Jacksonville 8
Norwalk 8
Nuremberg 8
Prineville 8
San Francisco 8
Shenzhen 8
Bengaluru 7
Chicago 7
Dearborn 7
Hebei 7
Hyderabad 7
Lappeenranta 7
Medford 7
Paris 7
Shenyang 7
Stockholm 7
Toronto 7
Bremen 6
Bình Phước 6
Bến Tre 6
Foshan 6
Hangzhou 6
Hải Dương 6
Montescudo 6
Montreal 6
Totale 4.958
Nome #
Follow-up del cancro del pancreas esocrino 455
A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. 262
Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations 233
Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. 210
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 208
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST) 206
Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). 205
Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. 205
Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. 205
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 191
MicroRNA profile in gastrointestinal stromal tumors (GISTs) and correlation with KIT/PDGFRA kinase genotype. 189
Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. 181
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 181
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 180
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib 176
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 175
Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. 170
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging 166
Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. 164
Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma 162
Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS) 160
Microscopic margins of resection in gastrointestinal stromal tumor (GIST): An analysis of 122 patients 155
Integrative analysis of gene expression profiling and high-resolution genomic copy number in gastrointestinal stromal tumor (GIST). 153
SDHA and SDHB mutations in KIT/PDGFRA WT gastrointestinal stromal tumors 150
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 146
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors 144
CRITICAL ANALYSIS ON MANAGEMENT OF GIST PATIENTS WITH EVENT TREE MODEL 143
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 142
Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy 133
The potential role of IGF1r in young adult patients with gastroinetstinal stromal tumor (GIST). 132
The interplay between inflammation, anti-angiogenic agents, and immune checkpoint inhibitors: Perspectives for renal cell cancer treatment 132
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 125
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients 124
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 123
Plasma androgen receptor in prostate cancer 121
Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors. 116
CAR-T cell therapy: A potential new strategy against prostate cancer 102
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients 96
null 90
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA 90
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 88
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 82
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial 79
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 74
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors 72
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 63
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 60
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 60
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib 59
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer 56
Correlation of [68Ga]Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study 55
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 55
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 52
Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics 47
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 44
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 38
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients 37
Psychosocial issues in long-term survivors of testicular cancer 37
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review 14
Totale 7.773
Categoria #
all - tutte 20.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.003


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021125 0 0 0 0 0 0 0 0 0 0 12 113
2021/2022704 59 10 24 49 58 27 40 43 28 66 181 119
2022/2023949 85 158 46 133 47 90 18 47 153 22 62 88
2023/2024303 34 38 22 33 15 72 6 16 24 9 19 15
2024/20251.340 79 174 137 120 196 80 58 66 23 96 51 260
2025/20263.230 237 231 222 186 374 112 657 160 701 287 63 0
Totale 7.773